| Name | Title | Contact Details |
|---|
Reglera is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VisuWell is the leader in patient-centered, innovative, and affordable virtual care solutions. The VisuWell platform is an easy-to-use, enterprise-ready, browser-deployed technology increasing healthcare access for health systems, ambulatory care organizations, and payors. VisuWell offers patients and providers a comprehensive telehealth experience for consults, triage, telemedicine visits, and remote patient monitoring over a wide variety of use cases and environments. VisuWell enables care organizations to utilize their own provider networks to offer easy-to-access, high-quality care. The VisuWell platform creates a tailored virtual experience accommodating 35+ use cases serving thousands of locations and helping millions of people to see healthcare differently.
Regional Medical Laboratories is a Battle Creek, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nature`s Sunshine Products manufactures and markets tablets and encapsulated herbal products, high-quality natural vitamins, food supplements, skin care and other complementary products. The Company has operations in the United States, South Korea, Mexico, Venezuela, Japan, Brazil, Canada, Central America, Colombia, Ecuador, Peru, the United Kingdom, Israel and Chile. The Company also exports its products to several other countries, including Argentina, Australia, Malaysia, New Zealand, Norway and the Russian Federation.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.